Daclatasvir dihydrochloride

SKU: orb1307451

Description

Daclatasvir dihydrochloride is an oral HCV NS5A inhibitor used in combination therapies for chronic hepatitis C. It is a key research tool for studying viral replication mechanisms in both in vitro and in vivo models, with a clinical profile associated with minimal hepatotoxicity.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 1009119-65-6
• MW: 811.8
• Purity: 99.84%
• Formula: C₄₀H₅₂Cl₂N₈O₆
• SMILES: Cl.Cl.COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c1ncc([nH]1)-c1ccc(cc1)-c1ccc(cc1)-c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C
• Target: HCV Protease
• Solubility: DMSO:55 mg/mL (67.75 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.23 mM)

Bioactivity

• Target IC50:
  NS5A33-202:8 nM (Kd)|HCV 5a:33 pM (EC50)|NS5A26-202:210 nM (Kd)|HCV 3a:146 pM (EC50)|HCV 1a:50 pM (EC50)|OATP1B:1.5 µM (IC50)|HCV 1b:9 pM (EC50)|HCV 4a:12 pM (EC50)|OCI:3.27 µM (IC50)|HCV 2a:71 pM (EC50)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Daclatasvir, Daclatasvir dihydrochloride, Daclatasvir Dihydrochloride, antiviral, BMS 790052, BMS 790052 Dihydrochloride, BMS790052, BMS-790052, BMS790052 Dihydrochloride, BMS-790052 dihydrochloride, BMS-790052 Dihydrochloride, OATP1B1, OATP1B3, inhibit, JFH-1, NS5A, Inhibitor, EBP-883, EBP 883, EBP883, Hepatitis C virus, HCVProtease, HCV Protease, HCV NS5A, HCV, genotypes, replicon

Compound Identifiers

PubChem CID

25154713